JNJ vs NKE: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$41.05
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
NKE has more upside to fair value
(+45.0%).
NKE trades at a lower forward P/E
(19.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
NKE |
| Current Price |
$253.85 |
$41.05 |
| Fair Value Estimate |
$198.76 |
$59.52 |
| Upside to Fair Value |
-21.7%
|
+45.0%
|
| Market Cap |
$611.1B |
$60.7B |
| Forward P/E |
29.3x
|
19.6x
|
| EV / EBITDA |
19.2x
|
14.2x
|
| Price / Sales |
6.3x
|
1.3x
|
| Price / FCF |
34.3x
|
57.9x
|
| Revenue Growth YoY |
+9.9%
|
-1.1%
|
| Gross Margin |
69.1%
|
42.9%
|
| Operating Margin |
26.9%
|
8.2%
|
| Return on Equity |
26.3%
|
22.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
1.73%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
NIKE, Inc. is a leading global athletic footwear and apparel company with a durable competitive moat supported by its strong brand, scale, and global distribution infrastructure. The company is currently led by CEO Elliott Hill, a seasoned Nike veteran who returned in October 2024 to navigate intensifying competition and channel complexity. Despite its market leadership and solid profitability me…
Accumulation Zones
| Metric |
JNJ |
NKE |
| Zone Low |
$149.07 |
$44.64 |
| Zone High |
$168.95 |
$50.59 |
| In Buy Zone? |
No
|
Yes
|